Silent Drain on Growing Minds: Iron Deficiency Anemia in Contemporary Pediatric Practice
1. Divya Sakhare
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Iron deficiency anemia remains the most widespread nutritional disorder of childhood, affecting cognitive potential, growth, and immunity long before hemoglobin falls. Recent American Academy of Pediatrics guidance has refined screening intervals, raised ferritin thresholds, and simplified once-daily oral iron dosing. This review synthesizes current epidemiology, pathophysiology, diagnostic standards, and evidence-based management for clinicians caring for infants, children, and adolescents, emphasizing prevention and the lasting developmental cost of delayed recognition.
Introduction
Every pediatrician has met the toddler who is pale, irritable, and oddly fond of ice or dirt, or the adolescent girl whose fatigue is dismissed as “just teenage life.” Behind many of these ordinary complaints lies iron deficiency anemia, still the commonest micronutrient deficiency on the planet. Globally, roughly two-fifths of children aged six to fifty-nine months are anemic, and iron deficiency accounts for the majority of cases. Even in high-resource settings the problem has not disappeared; national survey data continue to show iron deficiency in approximately fifteen percent of toddlers and more than ten percent of non-pregnant adolescent females.
What makes the condition especially troubling is that iron is required not only for hemoglobin but for the enzymes that drive myelination, neurotransmitter synthesis, and hippocampal development. Once deficiency has progressed far enough to produce anemia, some of the cognitive and behavioral effects may prove only partially reversible. The 2026 clinical report from the American Academy of Pediatrics therefore places renewed emphasis on earlier detection, higher diagnostic thresholds for ferritin, and pragmatic treatment regimens that families can actually follow. This article examines the current understanding of iron deficiency anemia in children within the familiar IMRAD framework, drawing on the latest guidelines and population data.
Methods
This narrative review is based on the 2026 AAP clinical report on prevention, screening, diagnosis, and treatment of iron deficiency and iron deficiency anemia from birth through adolescence, supplemented by recent systematic reviews, Global Burden of Disease estimates, and position statements from the World Health Organization and the American Society of Hematology. Emphasis was placed on literature published or updated between 2020 and 2026 that addresses epidemiology, laboratory cut-offs, dosing strategies, and developmental outcomes. No original data collection was performed; the synthesis aims to present a coherent clinical picture for practicing pediatricians and trainees.
Results
Epidemiology and Risk
Iron deficiency anemia is most prevalent in the first two years of life and again during the adolescent growth spurt, particularly in menstruating girls. In low- and middle-income countries the prevalence among preschool children frequently exceeds thirty to forty percent; even in the United States, iron deficiency (low body iron stores) affects about fifteen percent of toddlers. Preterm infants, exclusively breastfed infants after four to six months without supplementation, children whose diets rely heavily on cow’s milk, and adolescents with heavy menstrual bleeding constitute the highest-risk groups. Socioeconomic disadvantage, food insecurity, and certain cultural dietary patterns amplify risk further.
Pathophysiology
Iron stores accumulated in utero normally last four to six months in term infants. Thereafter, rapid expansion of blood volume and tissue mass demands a steady external supply. When intake or absorption fails to keep pace, storage iron (reflected by serum ferritin) declines first. Only after stores are exhausted does erythropoiesis become iron-limited, producing the classic microcytic, hypochromic anemia. Meanwhile, non-hematologic tissues suffer: brain iron is preferentially conserved, yet even mild deficiency impairs dopamine metabolism, myelination, and energy metabolism in neurons. The result is measurable decrements in attention, memory, and motor coordination that can persist into school age.
Clinical Manifestations
Early iron deficiency is often silent. As anemia develops, parents may notice pallor, fatigue, poor appetite, or pica. Toddlers sometimes display developmental plateaus or increased irritability. School-age children may present with declining academic performance or restless-legs symptoms. Adolescents frequently complain of unexplained tiredness, headaches, or reduced exercise tolerance. Physical findings, when present, include pale conjunctivae, tachycardia, and, in severe cases, a soft flow murmur. None of these signs is specific; laboratory evaluation remains essential.
Diagnosis
The 2026 AAP guidance recommends that laboratory screening consist of a complete blood count plus serum ferritin timed to the child’s greatest period of risk. Exclusively or predominantly breastfed infants should be screened at nine to twelve months; formula-fed infants after transition to cow’s milk or plant-based alternatives are screened at fifteen to eighteen months. Menstruating adolescents should be evaluated at least one year after menarche or by age fourteen.
Diagnostic thresholds have been raised. A serum ferritin of ≤20 ng/mL now indicates iron deficiency in young and school-aged children; ≤30 ng/mL is the threshold for adolescents and menstruating individuals. When low ferritin coexists with anemia (hemoglobin below age-specific norms and low mean corpuscular volume), the diagnosis of iron deficiency anemia is confirmed in the appropriate clinical context. Inflammation can elevate ferritin independently of iron stores; in such cases additional markers such as C-reactive protein or transferrin saturation may be required.
Prevention and Treatment
Prevention begins at birth with delayed cord clamping of thirty to sixty seconds, which meaningfully augments neonatal iron endowment. Preterm infants should receive 2–3 mg/kg/day of elemental iron once full enteral feeds are established. Exclusively breastfed term infants benefit from 1 mg/kg/day elemental iron starting by four months of age (or by six months if iron-rich complementary foods are introduced promptly). After six months, diets should emphasize iron-rich foods—meat, iron-fortified cereals, legumes—and limit cow’s milk to no more than 500 mL daily.
Once iron deficiency or iron deficiency anemia is diagnosed, the cornerstone of therapy is oral ferrous sulfate given once daily. For young children the recommended dose is 3 mg/kg elemental iron; for adolescents a fixed dose of 65 mg elemental iron is usually sufficient. Once-daily dosing improves adherence and appears as effective as divided doses while reducing gastrointestinal side effects. Treatment should continue for at least three months after hemoglobin normalizes so that stores can be replenished. Response is monitored with a rise in hemoglobin of at least 1 g/dL within four weeks and eventual normalization of ferritin.
Intravenous iron is reserved for children who cannot tolerate or absorb oral iron, have severe ongoing losses, or fail to respond despite documented adherence. Modern preparations such as ferric carboxymaltose are generally well tolerated in the pediatric age group when administered under appropriate monitoring. Transfusion is indicated only for children who are hemodynamically unstable or profoundly symptomatic; even then, iron therapy must follow.
Discussion
The recent upward revision of ferritin cut-offs is more than a laboratory technicality. Older thresholds of 12–15 ng/mL identified only the most depleted children; higher cut-offs capture iron deficiency earlier, before irreversible developmental injury occurs. Equally important is the simplification of oral iron regimens. Families are far more likely to complete a once-daily course than a three-times-daily schedule, and gastrointestinal tolerability is improved.
Yet diagnosis and treatment alone are insufficient. The long-term cognitive costs of iron deficiency—lower IQ scores, poorer school achievement, increased behavioral problems—underscore the need for robust primary prevention. Public-health measures such as iron fortification of staple foods, delayed cord clamping as standard obstetric practice, and targeted supplementation programs in high-risk communities remain essential. In clinical practice, attention to dietary history, menstrual patterns, and socioeconomic context allows earlier identification of children who will benefit from screening and counseling.
Limitations of current knowledge include the still-incomplete understanding of which neurodevelopmental deficits are fully reversible and the optimal duration of therapy in children with ongoing losses. Inflammation continues to complicate interpretation of ferritin, and research into pragmatic point-of-care markers is needed. Nevertheless, the tools now available—updated thresholds, simplified dosing, and clear screening schedules—equip pediatricians to reduce the burden of this entirely preventable condition.
In daily practice the difference is often quiet but consequential: the toddler who stops craving ice, the schoolchild whose attention improves, the adolescent girl who no longer feels chronically exhausted. These ordinary recoveries remind us that iron deficiency anemia, for all its global statistics, is ultimately a problem solved one child at a time through attentive clinical care and thoughtful public-health policy.
References
Powers JM, Heeney MM, Hord J, et al. Prevention, screening, diagnosis, and treatment of iron deficiency and iron deficiency anemia in infants, children, and adolescents: clinical report. Pediatrics. 2026;158(1):e2026077414.
World Health Organization. Guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: WHO; 2020.
American Society of Hematology. 2026 guidelines for diagnosis of iron deficiency. Blood Advances. 2026.
Global Burden of Disease Collaborative Network. Global burden of dietary iron deficiency 1990–2021. Nature Medicine. 2025.
World Health Organization. Anaemia in women and children. Global Health Observatory; 2024.
Powers JM. Iron deficiency in infants and children <12 years: screening, prevention, clinical manifestations, and diagnosis. UpToDate. Updated October 2026.
Powers JM. Iron deficiency in infants and children <12 years: treatment. UpToDate. Updated October 2026.
Iron Consortium at Oregon Health & Science University. Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations. Lancet Haematol. 2025;12(5):e376-e388.
Global prevalence of iron deficiency anaemia among children aged 5–12 years: a systematic review and meta-analysis. J Glob Health. 2026;16:04027.
Braat S, et al. Haemoglobin thresholds to define anaemia from age 6 months to 65 years. Lancet Haematol. 2024;11:e253-e264.